» Articles » PMID: 35956860

Free Linoleic Acid and Oleic Acid Reduce Fat Digestion and Absorption In Vivo As Potent Pancreatic Lipase Inhibitors Derived from Sesame Meal

Overview
Journal Molecules
Publisher MDPI
Specialty Biology
Date 2022 Aug 12
PMID 35956860
Authors
Affiliations
Soon will be listed here.
Abstract

Pancreatic lipase catalyzes the cleavage of triacylglycerols at the oil-water interface, and is known as the dominant determiner of dietary fat digestion. Reducing dietary fat digestion and absorption by modulating the activity of pancreatic lipase has become a favorable strategy to tackle obesity. Orlistat is, at present, the only pancreatic lipase inhibitor approved for the treatment of obesity; however, an array of gastrointestinal adverse effects associated with orlistat limits its tolerability. As a safe alternative to orlistat, a number of natural product-derived compounds with varying degrees of pancreatic lipase inhibitory activity have been reported. We herein reported that bioactivity-guided fractionation of sesame meal led to the identification of free linoleic acid and oleic acid as potent inhibitors of porcine pancreatic lipase in vitro with an IC50 of 23.1 µg/mL (82.4 µM) and 11.7 µg/mL (41.4 µM), respectively. In rats, a single oral dose of the mixture of these fatty acids significantly suppressed the elevation of blood triacylglycerol level following fat intake. These results substantiate the role of free linoleic acid and oleic acid as a novel class of natural product-derived functional molecules that act as pancreatic lipase inhibitors, and their potential for healthy, routine-based weight management.

Citing Articles

GC/MS Fatty Acid Profile of Marine-Derived Actinomycetes from Extreme Environments: Chemotaxonomic Insights and Biotechnological Potential.

Cunha M, Jorge A, Nunes M, Sousa J, Lanca M, Gomes da Silva M Mar Drugs. 2025; 23(1).

PMID: 39852503 PMC: 11767043. DOI: 10.3390/md23010001.


The Strong Inhibition of Pancreatic Lipase by Selected Indonesian Medicinal Plants as Anti-Obesity Agents.

Rahminiwati M, Iswantini D, Trivadila , Sianipar R, Sukma R, Indariani S Curr Issues Mol Biol. 2025; 47(1).

PMID: 39852154 PMC: 11764437. DOI: 10.3390/cimb47010039.


The cost-effectiveness analysis of semaglutide for the treatment of adult and adolescent patients with overweight and obesity: a systematic review.

Sarabi Asiabar A, Rezaei M, Jafarzadeh D, Rajaei S, Atefimanesh P, Soleimanpour S Eur J Clin Pharmacol. 2024; 80(12):1857-1870.

PMID: 39254692 DOI: 10.1007/s00228-024-03755-w.


Effects of Free Linoleic Acid and Oleic Acid in Sesame Meal Extract as Pancreatic Lipase Inhibitors on Postprandial Triglyceridemia: A Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Volunteers.

Li X, Yamada H, Morita S, Yamashita Y, Kim Y, Kometani T Nutrients. 2023; 15(7).

PMID: 37049588 PMC: 10097160. DOI: 10.3390/nu15071748.


Integrating microbiome and metabolome revealed microbe-metabolism interactions in the stomach of patients with different severity of peptic ulcer disease.

Wang C, Yu X, Lin H, Wang G, Liu J, Gao C Front Immunol. 2023; 14:1134369.

PMID: 36969184 PMC: 10034094. DOI: 10.3389/fimmu.2023.1134369.

References
1.
Khongkarat P, Traiyasut P, Phuwapraisirisan P, Chanchao C . First report of fatty acids in bee pollen with lipase inhibitory activity. PeerJ. 2022; 10:e12722. PMC: 8734463. DOI: 10.7717/peerj.12722. View

2.
Heck A, Yanovski J, Calis K . Orlistat, a new lipase inhibitor for the management of obesity. Pharmacotherapy. 2000; 20(3):270-9. PMC: 6145169. DOI: 10.1592/phco.20.4.270.34882. View

3.
Hu S, Wang L, Yang D, Li L, Togo J, Wu Y . Dietary Fat, but Not Protein or Carbohydrate, Regulates Energy Intake and Causes Adiposity in Mice. Cell Metab. 2018; 28(3):415-431.e4. DOI: 10.1016/j.cmet.2018.06.010. View

4.
Wise J . Covid-19: Highest death rates seen in countries with most overweight populations. BMJ. 2021; 372:n623. DOI: 10.1136/bmj.n623. View

5.
Pathak N, Rai A, Kumari R, Bhat K . Value addition in sesame: A perspective on bioactive components for enhancing utility and profitability. Pharmacogn Rev. 2014; 8(16):147-55. PMC: 4127822. DOI: 10.4103/0973-7847.134249. View